Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Williams

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Nature Medicine|February 9, 2023
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trialHatem Soliman, Deanna Hogue, Hyo Han, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
Infection|January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialMatthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|June 23, 2006
The first gene-based map of Lupinus angustifolius L.-location of domestication genes and conserved synteny with Medicago truncatulaMatthew N Nelson, Huyen T T Phan, Simon R Ellwood, et al.
Clinical Trials (London, England)|March 3, 2025
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.
Microbiology Spectrum|February 1, 2024
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)Matthew G Johnson, Julie M Strizki, Erin Jensen, et al.
Orphanet Journal of Rare Diseases|September 26, 2023
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical dataGema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, et al.
NEJM Evidence|February 6, 2024
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized AdultsYoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, et al.
Plos One|March 20, 2026
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysisVrinda Saraff, Pedro Arango Sancho, Justine Bacchetta, et al.
Orphanet Journal of Rare Diseases|February 3, 2026
Adolescents' experience of living with X-linked hypophosphataemia (XLH): a mixed-methods analysis of those who continued and discontinued burosumab treatment after end of skeletal growthVrinda Saraff, Pedro Arango-Sancho, Justine Bacchetta, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Nature Medicine|February 9, 2023
Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trialHatem Soliman, Deanna Hogue, Hyo Han, et al.
Lancet (London, England)|August 4, 2009
Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trialJeffrey L Lennox, Edwin DeJesus, Adriano Lazzarin, et al.
Infection|January 17, 2023
Molnupiravir for the treatment of COVID-19 in immunocompromised participants: efficacy, safety, and virology results from the phase 3 randomized, placebo-controlled MOVe-OUT trialMatthew G Johnson, Julie M Strizki, Michelle L Brown, et al.
TAG. Theoretical and Applied Genetics. Theoretische Und Angewandte Genetik|June 23, 2006
The first gene-based map of Lupinus angustifolius L.-location of domestication genes and conserved synteny with Medicago truncatulaMatthew N Nelson, Huyen T T Phan, Simon R Ellwood, et al.
Clinical Trials (London, England)|March 3, 2025
Impact of differences between interim and post-interim analysis populations on outcomes of a group sequential trial: Example of the MOVe-OUT studyYoseph Caraco, Matthew G Johnson, Joseph A Chiarappa, et al.
Microbiology Spectrum|February 1, 2024
Respiratory virus coinfections during the COVID-19 pandemic: epidemiologic analysis and clinical outcomes from the Phase 2/3 molnupiravir trial (MOVe-OUT)Matthew G Johnson, Julie M Strizki, Erin Jensen, et al.
Orphanet Journal of Rare Diseases|September 26, 2023
The International X-Linked Hypophosphatemia (XLH) Registry: first interim analysis of baseline demographic, genetic and clinical dataGema Ariceta, Signe Sparre Beck-Nielsen, Annemieke M Boot, et al.
NEJM Evidence|February 6, 2024
Phase 2/3 Trial of Molnupiravir for Treatment of Covid-19 in Nonhospitalized AdultsYoseph Caraco, Gordon E Crofoot, Pablo Andres Moncada, et al.
Plos One|March 20, 2026
The lived experience of adolescents with X-linked hypophosphataemia treated with burosumab at end of skeletal growth: a mixed-methods analysisVrinda Saraff, Pedro Arango Sancho, Justine Bacchetta, et al.
Orphanet Journal of Rare Diseases|February 3, 2026
Adolescents' experience of living with X-linked hypophosphataemia (XLH): a mixed-methods analysis of those who continued and discontinued burosumab treatment after end of skeletal growthVrinda Saraff, Pedro Arango-Sancho, Justine Bacchetta, et al.
Pageof 14